We are live on ! Find out more
NVS icon

Novartis

1,128 hedge funds and large institutions have $20.7B invested in Novartis in 2020 Q2 according to their latest regulatory filings, with 83 funds opening new positions, 408 increasing their positions, 421 reducing their positions, and 78 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more call options, than puts

Call options by funds: $203M | Put options by funds: $108M

6% more first-time investments, than exits

New positions opened: 83 | Existing positions closed: 78

2% more capital invested

Capital invested by funds: $20.4B → $20.7B (+$333M)

0.08% less ownership

Funds ownership: 9.71%9.63% (-0.08%)

0% less funds holding

Funds holding: 1,1331,128 (-5)

3% less repeat investments, than reductions

Existing positions increased: 408 | Existing positions reduced: 421

50% less funds holding in top 10

Funds holding in top 10: 3015 (-15)

Holders
1,128
Holders Change
-5
Holders Change %
-0.44%
% of All Funds
23.13%
Holding in Top 10
15
Holding in Top 10 Change
-15
Holding in Top 10 Change %
-50%
% of All Funds
0.31%
New
83
Increased
408
Reduced
421
Closed
78
Calls
$203M
Puts
$108M
Net Calls
+$95.1M
Net Calls Change
+$44.4M
Name Holding Trade Value Shares
Change
Change in
Stake
State Street
26
State Street
Massachusetts
$186M +$1.54M +17,817 +0.8%
MNG
27
Manning & Napier Group
New York
$186M -$7.81M -90,509 -4%
ClearBridge Investments
28
ClearBridge Investments
New York
$165M +$363K +4,201 +0.2%
Capital Research Global Investors
29
Capital Research Global Investors
California
$152M +$188K +2,180 +0.1%
Invesco
30
Invesco
Georgia
$140M -$30M -347,418 -18%
Goldman Sachs
31
Goldman Sachs
New York
$136M -$2.42M -27,991 -2%
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$131M +$1.17M +13,516 +0.9%
Principal Financial Group
33
Principal Financial Group
Iowa
$129M +$3.19M +37,010 +3%
SI
34
Scharf Investments
California
$114M -$2.36M -27,313 -2%
RJA
35
Raymond James & Associates
Florida
$112M +$1.06M +12,319 +1%
FAM
36
Fred Alger Management
New York
$111M -$22.4M -259,110 -17%
AG
37
Aperio Group
California
$105M +$5.01M +58,049 +5%
Ameriprise
38
Ameriprise
Minnesota
$102M -$3.28M -38,000 -3%
Natixis Advisors
39
Natixis Advisors
Massachusetts
$102M -$4.45M -51,554 -4%
Fidelity Investments
40
Fidelity Investments
Massachusetts
$86.6M -$31.1M -360,539 -27%
EARNEST Partners
41
EARNEST Partners
Georgia
$86.5M -$29.5M -342,241 -26%
BlackRock
42
BlackRock
New York
$82.4M -$8.22M -95,198 -9%
Capital World Investors
43
Capital World Investors
California
$78.9M +$48.9M +566,856 +168%
Rockefeller Capital Management
44
Rockefeller Capital Management
New York
$77.9M -$23.9M -277,255 -24%
Envestnet Asset Management
45
Envestnet Asset Management
Illinois
$77.3M +$8.33M +96,460 +12%
Chevy Chase Trust
46
Chevy Chase Trust
Maryland
$76.7M +$2.54M +29,458 +3%
Millennium Management
47
Millennium Management
New York
$75.8M +$11M +127,132 +17%
Westfield Capital Management
48
Westfield Capital Management
Massachusetts
$74.9M -$34.1M -394,721 -32%
SEI Investments
49
SEI Investments
Pennsylvania
$74.5M -$25.6M -296,114 -26%
Truist Financial
50
Truist Financial
North Carolina
$72.6M +$2.34M +27,160 +3%

NVS Hedge Fund Activity: Q2 2020 in Review

1,128 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2020, worth a combined $20.7B — up 1.6% from $20.4B a quarter earlier.

Buyers outnumbered sellers: 83 funds opened new NVS positions and 78 closed out — a net gain of 5 holders — while 408 added to existing stakes and 421 trimmed.

The largest buyer was Boston Partners, adding an estimated $290M. The largest seller was Dodge & Cox, cutting an estimated $310M.

  • 1,128 institutional investors held Novartis (NVS) as of Q2 2020, down from 1,133 in Q1 2020.
  • Funds reported $20.7B of Novartis stock for Q2 2020, up 1.6% quarter-over-quarter.
  • 83 funds opened new Novartis positions in Q2 2020 and 78 closed out, a net change of +5 holders.
  • The largest Novartis buyer in Q2 2020 was Boston Partners, an estimated $290M added.
  • The largest Novartis seller in Q2 2020 was Dodge & Cox, an estimated $310M sold.

Based on aggregated 13F filings for Q2 2020.